Cargando…
Using an Interaction Parameter in Model-Based Phase I Trials for Combination Treatments? A Simulation Study
There is growing interest in Phase I dose-finding studies studying several doses of more than one agent simultaneously. A number of combination dose-finding designs were recently proposed to guide escalation/de-escalation decisions during the trials. The majority of these proposals are model-based:...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796482/ https://www.ncbi.nlm.nih.gov/pubmed/33466469 http://dx.doi.org/10.3390/ijerph18010345 |
_version_ | 1783634692736548864 |
---|---|
author | Mozgunov, Pavel Knight, Rochelle Barnett, Helen Jaki, Thomas |
author_facet | Mozgunov, Pavel Knight, Rochelle Barnett, Helen Jaki, Thomas |
author_sort | Mozgunov, Pavel |
collection | PubMed |
description | There is growing interest in Phase I dose-finding studies studying several doses of more than one agent simultaneously. A number of combination dose-finding designs were recently proposed to guide escalation/de-escalation decisions during the trials. The majority of these proposals are model-based: a parametric combination-toxicity relationship is fitted as data accumulates. Various parameter shapes were considered but the unifying theme for many of these is that typically between 4 and 6 parameters are to be estimated. While more parameters allow for more flexible modelling of the combination-toxicity relationship, this is a challenging estimation problem given the typically small sample size in Phase I trials of between 20 and 60 patients. These concerns gave raise to an ongoing debate whether including more parameters into combination-toxicity model leads to more accurate combination selection. In this work, we extensively study two variants of a 4-parameter logistic model with reduced number of parameters to investigate the effect of modelling assumptions. A framework to calibrate the prior distributions for a given parametric model is proposed to allow for fair comparisons. Via a comprehensive simulation study, we have found that the inclusion of the interaction parameter between two compounds does not provide any benefit in terms of the accuracy of selection, on average, but is found to result in fewer patients allocated to the target combination during the trial. |
format | Online Article Text |
id | pubmed-7796482 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-77964822021-01-10 Using an Interaction Parameter in Model-Based Phase I Trials for Combination Treatments? A Simulation Study Mozgunov, Pavel Knight, Rochelle Barnett, Helen Jaki, Thomas Int J Environ Res Public Health Article There is growing interest in Phase I dose-finding studies studying several doses of more than one agent simultaneously. A number of combination dose-finding designs were recently proposed to guide escalation/de-escalation decisions during the trials. The majority of these proposals are model-based: a parametric combination-toxicity relationship is fitted as data accumulates. Various parameter shapes were considered but the unifying theme for many of these is that typically between 4 and 6 parameters are to be estimated. While more parameters allow for more flexible modelling of the combination-toxicity relationship, this is a challenging estimation problem given the typically small sample size in Phase I trials of between 20 and 60 patients. These concerns gave raise to an ongoing debate whether including more parameters into combination-toxicity model leads to more accurate combination selection. In this work, we extensively study two variants of a 4-parameter logistic model with reduced number of parameters to investigate the effect of modelling assumptions. A framework to calibrate the prior distributions for a given parametric model is proposed to allow for fair comparisons. Via a comprehensive simulation study, we have found that the inclusion of the interaction parameter between two compounds does not provide any benefit in terms of the accuracy of selection, on average, but is found to result in fewer patients allocated to the target combination during the trial. MDPI 2021-01-05 2021-01 /pmc/articles/PMC7796482/ /pubmed/33466469 http://dx.doi.org/10.3390/ijerph18010345 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Mozgunov, Pavel Knight, Rochelle Barnett, Helen Jaki, Thomas Using an Interaction Parameter in Model-Based Phase I Trials for Combination Treatments? A Simulation Study |
title | Using an Interaction Parameter in Model-Based Phase I Trials for Combination Treatments? A Simulation Study |
title_full | Using an Interaction Parameter in Model-Based Phase I Trials for Combination Treatments? A Simulation Study |
title_fullStr | Using an Interaction Parameter in Model-Based Phase I Trials for Combination Treatments? A Simulation Study |
title_full_unstemmed | Using an Interaction Parameter in Model-Based Phase I Trials for Combination Treatments? A Simulation Study |
title_short | Using an Interaction Parameter in Model-Based Phase I Trials for Combination Treatments? A Simulation Study |
title_sort | using an interaction parameter in model-based phase i trials for combination treatments? a simulation study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796482/ https://www.ncbi.nlm.nih.gov/pubmed/33466469 http://dx.doi.org/10.3390/ijerph18010345 |
work_keys_str_mv | AT mozgunovpavel usinganinteractionparameterinmodelbasedphaseitrialsforcombinationtreatmentsasimulationstudy AT knightrochelle usinganinteractionparameterinmodelbasedphaseitrialsforcombinationtreatmentsasimulationstudy AT barnetthelen usinganinteractionparameterinmodelbasedphaseitrialsforcombinationtreatmentsasimulationstudy AT jakithomas usinganinteractionparameterinmodelbasedphaseitrialsforcombinationtreatmentsasimulationstudy |